Genmab — Juni 2019

E_L

not sure if i posted this the other week on patient age subgroup analysis of the phase 3 CASTOR and POLLUX studies. https://www.ncbi.nlm.nih.gov/pubmed/31221782

E_L

@Bulder high age is not the same as high risk, but a certain correlation must be there

Bulder

A little bit further down he says: Dose attenuated VRd for high risk

E_L

Did you see that Rajkumar comment in the tweet i posted earlier We just completed a trial of VRd vs KRd.... We actually wanted to add a third arm with DRd. But there was no appetite for amendment among the review panels. Looks like some people want some questions to be better left unanswered.

E_L

Would be really interesting to know which one of the Big Pharma stopped that comparison....

Bulder

Review panel are doctors?

nohope

Der er vel stadigvæk nogen der skal betale ?

E_L

maybe i am too cynical, but i think the big pharma companies have a large say in what is being tried or not.... Just denying sponsoring the drugs will already kill many trials...

nohope

Me too ....

E_L

me to, is that on also being too cynical

troldmanden

Thats how it has always been. So absolotly no surprice there....

troldmanden

The one who pays deside what to be tested

troldmanden

Only the smaller trials driven on universities is "independen"

nohope

Definitely on the cynical side....

nohope

Nothing like age and experience to make you cynical.

JørgenVarnæs

Det skulle da lige være den fulde plade af bull-shit bingo, der flyder fra GEN, når det kommer til strategi

nohope

What is the best about Dara ? The best is that it does have some effect on MM, but it doesn´t cure the patient, it keeps him alive - so we can benefit from him for years.

hda

That’s cynical alright!

Legolas23

Er der nogen som har fundet noget om milestone. Den kan ikke være af ubetydelig størrelse, men kommer måske først når første patient i 1. linie er behandlet?

nohope

Well, den er med sikkerhed indregnet i Genmabs egne estimater - stor eller lille.